Navigation Links
Mentice VIST(TM) New and Enhanced Carotid and Coronary Training Modules Take Medical Simulation Training to the Next Level
Date:12/1/2008

GOTHENBURG, Sweden, December 1 /PRNewswire/ -- Mentice proudly announces the launch of two new products for endovascular simulation training - the Mentice VIST 7.7 enhanced training modules for Carotid and Coronary interventions. New features such as vital signs, complications, medication management and measurement functionality add to the clinical realism and enhance the educational value of simulation training.

"Features like vital signs and complications imply a dynamic patient representation which requires further decision making, planning and patient interactions," said Goran Malmberg, President/CEO of Mentice.

"On top of the new functionalities, we are launching new anatomical content and further training alternatives such as CTO (Chronic Total Occlusion) lesions and cases that enable transradial access," Malmberg continues. "This launch truly shows that Mentice continues to be a driver of the medical simulation market and it further strengthens our position as a leader in the field of endovascular simulation training."

With the launch of the VIST 7.7 training modules Mentice adds to the already wide range of training opportunities for Carotid and Coronary interventions - all together a total of 42 patient cases. A summary of the new features are presented below.

Vital signs - All cases have vital signs recognition and response.

Complications - A select number of cases include complications that will occur as a result of user actions. One example, engaging a catheter too deeply into an ostium may result in vascular spasm.

Medication management - Medication administration is included to manage the complications the trainees encounter. One example of this would be the injection of Nitroglycerin for treatment of a spasm.

Measurement functionality - New measurement functionality has been added to allow the users to easily measure the diameters and length of lesions, reference vessels, etc - adding additional realism to the equipment selection process.

Mentice - improving patient safety

Mentice is a world leader in medical simulation, providing qualified solutions for training, education and assessment opportunities. With a focus on minimally invasive techniques and procedures, Mentice develops simulation systems for training in a safe environment within the fields of endovascular intervention and endoscopic surgery. The advantages of training with Mentice solutions are well documented enhancing clinical performance, reducing cost, and, in the long term, improving patient safety.

    For further information, please contact
    Goran Malmberg, President/CEO of Mentice.
    Office: +46-31-33-99-401,
    Web:http://www.mentice.com


'/>"/>
SOURCE Mentice AB
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Mentice, Inc. Announces Appointment of Vice-President, Sales and Marketing, Americas
2. Mentice, Inc. Expands Its North American Sales and Clinical Presence With the Hiring of Jeff Sirek as Director of Educational Sales-East and Sue Landsman as Clinical Applications Manager for the Americas.
3. EDAP Launches Enhanced Communication Plans at SIU Paris Congress
4. Enhanced PrecyseCode 2X(TM) Further Accelerates Remote Coding and Improves Cash Flow for Hospitals
5. Joint Juice Launches New Ready-to-Drink Glucosamine & Vitamin-Enhanced Dietary Supplement Water Nationwide
6. The American Pain Foundation (APF) and The HealthCentral Network Collaborate to Develop Enhanced Internet Resources for People with Pain
7. PreViser Launches New Website and Enhanced Version of Its Oral Disease and Risk Assessment Software
8. NHP Reports Third Quarter 2007 Revenue and FFO Growth and Enhanced Disclosure Information
9. Brookdale Senior Living Announces Enhanced Web Site
10. T cell immunity enhanced by timing of interleukin-7 therapy
11. The HealthCentral Network and Sister to Sister Form Alliance to Develop Enhanced Online Resources
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... PurhealthRX , a leading Health ... technology. Applying the Purzorb™process to full spectrum CBD oil will revolutionize the rapidly growing ... form that can be easily incorporated into liquid products, while reducing costs to end ...
(Date:10/13/2017)... ... October 13, 2017 , ... Apple Rehab Shelton Lakes , ... mock evacuation of the facility as part of a disaster drill on October 3rd. ... EMS and Shelton City Emergency Manager, as well as the Connecticut Long Term ...
(Date:10/13/2017)... York, NY (PRWEB) , ... October 13, 2017 , ... ... influential people in business to advocate for action towards gender equality at their inaugural ... views from around the globe, and reached a social audience of over 3 million. ...
(Date:10/13/2017)... ... 13, 2017 , ... Talented host, actor Rob Lowe, is ... a new episode of "Success Files," which is an award-winning educational program broadcasted ... each subject in-depth with passion and integrity. , Sciatica occurs when the sciatic ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: ... “America On The Brink” is the creation of published author, William Nowers. ... As a WWII veteran, he spent thirty years in the Navy. Following ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... PHILADELPHIA , Oct. 2, 2017 Halo Labs announces ... particle analysis system called the HORIZON at MIBio 2017 in ... analyzes subvisible and visible particulate matter in biopharmaceutical samples with unprecedented ... use of the novel technique Backgrounded Membrane Imaging. ... The HORIZON subvisible particle analysis system ...
(Date:9/27/2017)... Sept. 27, 2017  Commended for their devotion to personalized ... Ranked as number one in the South Florida Business Journal,s ... Inc. 5000 yearly list, the national specialty pharmacy has found ... Bardisa will soon be honored by SFBJ as the ... Set to receive his award in October, Bardisa ...
(Date:9/23/2017)... Janssen Biotech, Inc. (Janssen) announced today that ... U.S. Food and Drug Administration (FDA) for the Biologics ... treatment of moderately to severely active rheumatoid arthritis (RA). ... needed to further evaluate the safety of sirukumab in ... "We are disappointed ...
Breaking Medicine Technology: